
Las Vegas-Patients with subfoveal cho-roidal neovascularization (CNV) who received monthly injections of ranibizumab (Lucentis, Genentech) for 3 months and quarterly thereafter fared better than those patients receiving sham treatment in the PIER study. Vision in patients receiving the quarterly injections in this trial was not as good as that in patients who received monthly doses of ranibizumab for the duration of the MARINA and ANCHOR studies, however, reported Peter K. Kaiser, MD.